These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 1695120)
1. Plasma sex hormone binding globulin in patients with prostatic carcinoma. Grasso M; Buonaguidi A; Mondina R; Borsellino G; Lania C; Banfi G; Rigatti P Cancer; 1990 Jul; 66(2):354-7. PubMed ID: 1695120 [TBL] [Abstract][Full Text] [Related]
2. Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer. Rannikko S; Adlercreutz H Prostate; 1983; 4(3):223-9. PubMed ID: 6189106 [TBL] [Abstract][Full Text] [Related]
3. Sex-hormone-binding globulin in the plasma of normal men and patients with benign prostatic hypertrophy. Minguell JJ; Merino J; Valladares LE; Troncoso S Arch Androl; 1979; 3(2):167-71. PubMed ID: 92918 [TBL] [Abstract][Full Text] [Related]
4. [Studies on sex hormone-binding globulin in the prostate]. Jiang H; Chen Z Zhonghua Nan Ke Xue; 2004 Jun; 10(6):443-4, 448. PubMed ID: 15267211 [TBL] [Abstract][Full Text] [Related]
5. Plasma sex hormone-binding globulin binding capacity in benign prostatic hypertrophy and prostatic carcinoma: comparison with an age dependent rise in normal human males. Dennis M; Horst HJ; Krieg M; Voigt KD Acta Endocrinol (Copenh); 1977 Jan; 84(1):207-14. PubMed ID: 64100 [No Abstract] [Full Text] [Related]
6. Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy. Salonia A; Gallina A; Briganti A; Zanni G; Suardi N; Capitanio U; Colombo R; Bertini R; Freschi M; Guazzoni G; Rigatti P; Montorsi F BJU Int; 2011 Apr; 107(8):1243-9. PubMed ID: 20883480 [TBL] [Abstract][Full Text] [Related]
7. Prospective study of sex hormone levels and risk of prostate cancer. Gann PH; Hennekens CH; Ma J; Longcope C; Stampfer MJ J Natl Cancer Inst; 1996 Aug; 88(16):1118-26. PubMed ID: 8757191 [TBL] [Abstract][Full Text] [Related]
8. Studies on the role of sex-hormone-binding globulin (SHBG) in benign prostatic hypertrophy in men. I. Clinical research. Pachman A Int Urol Nephrol; 1984; 16(2):141-7. PubMed ID: 6206017 [TBL] [Abstract][Full Text] [Related]
9. Sex hormone binding globulin in carcinoma of the prostate. Houghton AL; Turner R; Cooper EH Br J Urol; 1977 Jun; 49(3):227-32. PubMed ID: 562212 [TBL] [Abstract][Full Text] [Related]
10. Pretreatment plasma levels of testosterone and sex hormone binding globulin binding capacity in relation to clinical staging and survival in prostatic cancer patients. Haapiainen R; Rannikko S; Alfthan O; Adlercreutz H Prostate; 1988; 12(4):325-32. PubMed ID: 3393494 [TBL] [Abstract][Full Text] [Related]
11. [Effect of radix urticae extract and its several secondary extracts on blood SHBG in benign prostate hyperplasia]. Schmidt K Fortschr Med; 1983 Apr; 101(15):713-6. PubMed ID: 6189775 [TBL] [Abstract][Full Text] [Related]
12. Sex hormone-binding globulin in the diagnosis of peripheral tissue resistance to thyroid hormone: the value of changes after short term triiodothyronine administration. Sarne DH; Refetoff S; Rosenfield RL; Farriaux JP J Clin Endocrinol Metab; 1988 Apr; 66(4):740-6. PubMed ID: 3346353 [TBL] [Abstract][Full Text] [Related]
13. Sex hormone-binding globulin: a novel marker for nodal metastases prediction in prostate cancer patients undergoing extended pelvic lymph node dissection. Salonia A; Briganti A; Gallina A; Karakiewicz P; Shariat S; Freschi M; Zanni G; Capitanio U; Bosi E; Rigatti P; Montorsi F Urology; 2009 Apr; 73(4):850-5. PubMed ID: 19038425 [TBL] [Abstract][Full Text] [Related]
14. Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study. de Jong FH; Oishi K; Hayes RB; Bogdanowicz JF; Raatgever JW; van der Maas PJ; Yoshida O; Schroeder FH Cancer Res; 1991 Jul; 51(13):3445-50. PubMed ID: 1711411 [TBL] [Abstract][Full Text] [Related]
16. Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels. Rył A; Rotter I; Grzywacz A; Małecka I; Skonieczna-Żydecka K; Grzesiak K; Słojewski M; Szylińska A; Sipak-Szmigiel O; Piasecka M; Walczakiewicz K; Laszczyńska M Int J Environ Res Public Health; 2017 Oct; 14(11):. PubMed ID: 29084161 [No Abstract] [Full Text] [Related]
17. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Kristal AR; Schenk JM; Song Y; Arnold KB; Neuhouser ML; Goodman PJ; Lin DW; Stanczyk FZ; Thompson IM Am J Epidemiol; 2008 Dec; 168(12):1416-24. PubMed ID: 18945688 [TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Mantzoros CS; Tzonou A; Signorello LB; Stampfer M; Trichopoulos D; Adami HO Br J Cancer; 1997; 76(9):1115-8. PubMed ID: 9365156 [TBL] [Abstract][Full Text] [Related]
19. Preoperative serum sex hormone-binding globulin as a predictive marker for extraprostatic extension of tumor in patients with clinically localized prostate cancer. Lee SE; Chung JS; Han BK; Park CS; Moon KH; Byun SS; Choe G; Hong SK Eur Urol; 2008 Dec; 54(6):1324-32. PubMed ID: 18339472 [TBL] [Abstract][Full Text] [Related]
20. Serum levels of sex hormone binding globulin (SHBG) are not predictive of prostate cancer diagnosis and aggressiveness: results from an Italian biopsy cohort. De Nunzio C; Lombardo R; Albisinni S; Gacci M; Tubaro A Int Braz J Urol; 2013; 39(6):793-9. PubMed ID: 24456771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]